On July 27, 2016, an Institutional Review Board (IRB) approved the third protocol amendment for our ongoing Phase 1 study of the psychological effects of MDMA when taken in a therapeutic setting by healthy volunteers. Enrollment in this study is limited to therapists in training to work on MAPS-sponsored clinical trials of MDMA-assisted psychotherapy for PTSD, with enrollment by invitation only. The amendment included increasing total enrollment to 100 participants and adding a second site in Boulder, Colorado, under the direction of Marcela Ot’alora, M.A., L.P.C., in order to increase enrollment to cover training needs over the next five years. We are currently preparing to request an order of 15 grams of MDMA from the DEA to be used in this study. Learn more…
